Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900982 | 0.84 | TSHR (0.57) | GAALMNAMEN1KMT2AMAPT | |
| SCHEMBL25974456 | 0.82 | HTR2A (0.46) | LMNAMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL24811008 | 0.80 | CYP3A4 (0.42) | LMNAMAPTSMN1; SMN2CYP3A4HTR2A | |
| SCHEMBL10821843 | 0.79 | ALDH1A1 (0.46) | GAALMNAMEN1KMT2AMAPT | |
| SCHEMBL12180428 | 0.78 | MEN1 (0.44) | GAALMNAMEN1KMT2AMAPT | |
| SCHEMBL900859 | 0.78 | ALDH1A1 (0.39) | LMNAMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL14297591 | 0.77 | HTT (0.40) | LMNAMEN1KMT2AHTR2ATSHR | |
| SCHEMBL680002 | 0.76 | HSD17B10 (0.45) | LMNAMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL10203281 | 0.76 | RXRA (0.42) | LMNAMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL14018146 | 0.76 | L3MBTL1 (0.39) | GAALMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2014008458-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| EP-2621922-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| WO-2012041858-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GAA 1018/4885LMNA 170/4885MEN1 3823/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | GAA 1886/4885LMNA 1088/4885MEN1 2822/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | GAA 1337/4885LMNA 1867/4885MEN1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.